Integer Holdings Corp（ITGR）财务数据ITGRInteger Holdings Corp

Integer Holdings Corp (ITGR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cardio & Vascular, accounting for 60.4% of total sales, equivalent to $280.31M. Other significant revenue streams include Cardiac Rhythm Management & Neuromodulation and Advanced Surgical, Orthopedics & Portable Medical. Understanding this composition is critical for investors evaluating how ITGR navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Integer Holdings Corp maintains a gross margin of 24.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.02%, while the net margin is 5.09%. These profitability ratios, combined with a Return on Equity (ROE) of 7.50%, provide a clear picture of how effectively ITGR converts its operational activities into shareholder value.

In the context of the broader market, ITGR competes directly with industry leaders such as CELC and NVST. With a market capitalization of $4.26B, it holds a significant position in the sector. When comparing efficiency, ITGR's gross margin of 24.71% stands against CELC's N/A and NVST's 56.71%. Such benchmarking helps identify whether Integer Holdings Corp is trading at a premium or discount relative to its financial performance.

Integer Holdings has shown a year-to-date change of +63.23% and a 1-year change of +17.16%. However, the revenue for Q2 2026 was $464.11 million, which is a 2.5% decline year-over-year, indicating potential challenges ahead.